Global healthcare supply chains are expanding fill-finish manufacturing infrastructure to meet unprecedented demand for GLP-1 receptor agonists. Bottlenecks in sterile injectable packaging have limited market penetration despite high clinical efficacy.
Contract Manufacturing Spend
Major pharmaceutical firms have allocated over $12 billion toward contract development and manufacturing organization partnerships. New facility activations in North America aim to double output by Q4.
Insurance Coverage Friction
Payer negotiations remain complex as self-insured employers scrutinize prescription drug expenditures. Clinical trial extensions targeting off-label applications will dictate long-term reimbursement policies.